sulpiride has been researched along with Obesity in 14 studies
Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed)
sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the role of insulin in the development of obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in 40 female rats during the peak of sulpiride-induced weight gain and in 40 vehicle-treated animals." | 7.70 | Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride. ( Baptista, T; Hernández, L; LaCruz, A, 1998) |
| "5-16 mg/kg/ip for 21 days) (a) affects body weight and food intake in gonadally-intact and drug-free female rats, (b) prevents obesity, hyperphagia, hyperprolactinemia and vaginal cycle disruption induced by long-term administration of the antipsychotic drug sulpiride (SUL, 20 mg/kg/ip for 21 days), or (c) reverses the acute hyperphagia induced by SUL (15 microg bilaterally), when directly applied in the perifornical lateral hypothalamus (PFLH)." | 7.70 | Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. ( Acosta, A; Baptista, T; Colasante, C; de Mendoza, S; de Quijada, M; Hernández, L; Lacruz, A; Mendoza, JM, 2000) |
| " Similarly, obesity induced by the neuroleptic drug sulpiride (SUL, 20 mg/kg/ip for 21 days) was prevented by AM only at the dose of 100 mg/kg." | 7.69 | Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. ( Alastre, T; Alternus, M; Araujo de Baptista, E; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; López, ME; Musseo, E; Páez, X; Teneud, L; Weiss, SR, 1997) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| " First, in preclinical experiments in female rats the estradiol antagonist/agonist drug tamoxifen or estradiol itself have been shown to completely prevent the obesity provoked by the AP sulpiride, and to induce an endocrine-metabolic milieu that seems to counteract AP-induced obesity." | 4.80 | Body weight gain induced by antipsychotic drugs: mechanisms and management. ( Baptista, T, 1999) |
| "To assess the role of insulin in the development of obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in 40 female rats during the peak of sulpiride-induced weight gain and in 40 vehicle-treated animals." | 3.70 | Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride. ( Baptista, T; Hernández, L; LaCruz, A, 1998) |
| " To assess the role of insulin in the development of the obesity induced by antipsychotic drugs, a glucose tolerance test was conducted in female rats after 0 or 30 days of sulpiride administration." | 3.70 | Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs. ( Alvarez, L; Baptista, T; de Mendoza, S; Hernández, L; Lacruz, A, 1999) |
| "5-16 mg/kg/ip for 21 days) (a) affects body weight and food intake in gonadally-intact and drug-free female rats, (b) prevents obesity, hyperphagia, hyperprolactinemia and vaginal cycle disruption induced by long-term administration of the antipsychotic drug sulpiride (SUL, 20 mg/kg/ip for 21 days), or (c) reverses the acute hyperphagia induced by SUL (15 microg bilaterally), when directly applied in the perifornical lateral hypothalamus (PFLH)." | 3.70 | Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats. ( Acosta, A; Baptista, T; Colasante, C; de Mendoza, S; de Quijada, M; Hernández, L; Lacruz, A; Mendoza, JM, 2000) |
| "The weight gain and hyperphagia induced by chronic administration of sulpiride in female rats were not prevented by the concomitant administration of an extra source of sodium." | 3.69 | Hyponatremia and neuroleptic-induced obesity in rats. ( Baptista, T; Catalán, M; Hernández, L; Silva, E; Teneud, L, 1994) |
| " Similarly, obesity induced by the neuroleptic drug sulpiride (SUL, 20 mg/kg/ip for 21 days) was prevented by AM only at the dose of 100 mg/kg." | 3.69 | Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates. ( Alastre, T; Alternus, M; Araujo de Baptista, E; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; López, ME; Musseo, E; Páez, X; Teneud, L; Weiss, SR, 1997) |
| "3." | 1.30 | Mechanism of the neuroleptic-induced obesity in female rats. ( Acosta, A; Albornoz, MA; Baptista, T; Contreras, Q; de Quijada, M; Hernández, L; LaCruz, A; Páez, X; Teneud, L, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.14) | 18.7374 |
| 1990's | 6 (42.86) | 18.2507 |
| 2000's | 6 (42.86) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Wei, H | 1 |
| Zapata, RC | 1 |
| Lopez-Valencia, M | 1 |
| Aslanoglou, D | 1 |
| Farino, ZJ | 1 |
| Benner, V | 1 |
| Osborn, O | 1 |
| Freyberg, Z | 1 |
| McCarthy, MJ | 1 |
| Lin, CC | 1 |
| Bai, YM | 1 |
| Wang, YC | 1 |
| Chen, TT | 1 |
| Lai, IC | 1 |
| Chen, JY | 1 |
| Chen, SY | 1 |
| Gau, SS | 1 |
| Liou, YJ | 1 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Hajnal, A | 1 |
| Margas, WM | 1 |
| Covasa, M | 1 |
| Sannia, A | 1 |
| Benna, GM | 1 |
| Silva, E | 1 |
| Catalán, M | 1 |
| Hernández, L | 7 |
| Teneud, L | 3 |
| Baptista, T | 9 |
| López, ME | 1 |
| Contreras, Q | 2 |
| Alastre, T | 1 |
| de Quijada, M | 3 |
| Araujo de Baptista, E | 1 |
| Alternus, M | 1 |
| Weiss, SR | 1 |
| Musseo, E | 1 |
| Páez, X | 2 |
| Albornoz, MA | 1 |
| Acosta, A | 2 |
| LaCruz, A | 5 |
| Alvarez, L | 1 |
| de Mendoza, S | 3 |
| Mendoza-Guillén, JM | 1 |
| Colasante, C | 1 |
| Mendoza, JM | 1 |
2 reviews available for sulpiride and Obesity
| Article | Year |
|---|---|
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
Body weight gain induced by antipsychotic drugs: mechanisms and management.
Topics: Animals; Antipsychotic Agents; Body Weight; Dose-Response Relationship, Drug; Endocrine System; Estr | 1999 |
12 other studies available for sulpiride and Obesity
| Article | Year |
|---|---|
Dopamine D
Topics: Animals; Blood Glucose; Bromocriptine; Circadian Rhythm; Diabetes Mellitus, Type 2; Dopamine; Dopami | 2020 |
Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics.
Topics: Adult; Amisulpride; Antipsychotic Agents; Body Weight; Energy Metabolism; Female; Follow-Up Studies; | 2009 |
Altered dopamine D2 receptor function and binding in obese OLETF rat.
Topics: Analysis of Variance; Animals; Behavior, Animal; Brain; Conditioning, Operant; Disease Models, Anima | 2008 |
Prolactin response to stimulation in obesity.
Topics: Adult; Body Weight; Humans; Middle Aged; Obesity; Prolactin; Sulpiride; Thyrotropin-Releasing Hormon | 1983 |
Hyponatremia and neuroleptic-induced obesity in rats.
Topics: Animals; Drinking; Female; Hyperphagia; Obesity; Potassium; Rats; Rats, Wistar; Sodium; Sulpiride; W | 1994 |
Amantadine in the treatment of neuroleptic-induced obesity in rats: behavioral, endocrine and neurochemical correlates.
Topics: Amantadine; Animals; Antipsychotic Agents; Body Weight; Dopamine; Eating; Estrus; Female; Hypothalam | 1997 |
Mechanism of the neuroleptic-induced obesity in female rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Energ | 1998 |
Glucose tolerance and serum insulin levels in an animal model of obesity induced by the antipsychotic drug, sulpiride.
Topics: Animals; Antipsychotic Agents; Area Under Curve; Blood Glucose; Disease Models, Animal; Eating; Estr | 1998 |
Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Female; Glucose Tolerance Test; Hyperinsulini | 1999 |
Antipsychotic drug-induced obesity in rats: correlation between leptin, insulin and body weight during sulpiride treatment.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Female; Glucose Tolerance Test; Insulin; Leptin; Multi | 2000 |
Naltrexone does not prevent the weight gain and hyperphagia induced by the antipsychotic drug sulpiride in rats.
Topics: Animals; Antipsychotic Agents; Diestrus; Eating; Female; Hyperphagia; Naltrexone; Narcotic Antagonis | 2000 |
Mechanisms of weight gain induced by antipsychotic drugs.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Dopamine Antagoni | 2002 |